Background {#Sec1}
==========

In developed world, cancer and cardiac disease play a major role in causing morbidity and mortality \[[@CR1]\]. Due to recent therapeutic advancements, 5-year survival for early stage breast cancer increased from 79% to 88% during the last two decades \[[@CR2]--[@CR5]\]. Similarly, survival rates have also been increased in other solid and hematological cancers as well as non-hodgkin lymphoma and testicular cancer \[[@CR6]\].

Numerous drugs are administered to the patients with advanced cancer in order to treat their malignancy, its related ailments (e.g., pain), comorbid illnesses (e.g., heart disease, diabetes, dyslipidemia), and mitigate adverse effects induced by chemotherapy (e.g., nausea and vomiting). Certainly, multiple therapies make cancer patients vulnerable to potentially unsafe drug-drug interactions (DDIs) and it can be worsened in the presence of aberrant organ function (heart, liver, and kidney) \[[@CR7]\].

Since last few years, cancer patients have been predisposed to substantial medical complications in the form of heart diseases \[[@CR8]\]. A distinctive range of cardiovascular anomalies including, myocardial toxicity, ischemia, hypertension and arrhythmia \[[@CR9]--[@CR13]\] either directly or indirectly (inappropriate lifestyle) have been associated with new cancer therapies \[[@CR1]\]. Moreover, anticancer agents and supportive care therapy may cause various cardiac rhythm disorders and most remarkable feature is prolonged QT interval which can ultimately lead to ventricular arrhythmias. Concomitant use of supportive care therapy and cancer medications may cause prolongation of QT interval \[[@CR1]\].

The QT interval on an electrocardiography (ECG) rhythm strip indicates phases of ventricular depolarization and consequent repolarization and its measurement is taken from the point where QRS complex begins to the end of T wave \[[@CR7]\]. A delay in the cardiac repolarization phase leads to the electrophysiological disturbances and subsequent torsades de pointes (TdP) \[[@CR14], [@CR15]\]. TdP is a rare form of fatal polymorphic ventricular tachycardia that is often illustrated by the twisting of points on an ECG \[[@CR7]\]. Currently, pharmacoepidemiologic data regarding prevalence and nature of QT prolonging drug-drug interactions (QT-DDIs) in cancer patients is limited and there are certain areas which need to be explored. Issue of QT-DDIs in cancer patients is a poorly addressed area. To the best of our knowledge, there is no specific study regarding the prevalence of QT-DDIs in oncology settings. There are some studies which have worked on the prevalence and nature of overall potential DDIs in cancer patients \[[@CR16]--[@CR18]\]. As the main aims of these studies were to explore all types of DDIs in a generalized manner, therefore limited considerations have been given to QT-DDIs. All of these studies have elaborated in their discussions that proper attention should be given to QT-DDIs and their associated negative consequences in cancer patients \[[@CR16]--[@CR18]\]. Therefore, specific work is needed in cancer patients to explore the prevalence of QT-DDIs, possible risk factors, extent of the risk of QTc prolongation and possible predictors. Lack of scientific evidence regarding prescribing pattern of QT prolonging medications, QT-DDIs and QTc prolongation may predispose cancer patients to TdP. Such studies will be helpful to improve clinical practice and ensure patients' safety.

Aim of the study {#Sec2}
----------------

The aim of this study was to investigate the frequency of QT prolonging drugs and their TdP risk; and QT-DDIs, their levels of severity and documentation, predictors and TdP risk of drugs involved in QT-DDIs.

Methods {#Sec3}
=======

Study design and settings {#Sec4}
-------------------------

This was a multicenter cross-sectional retrospective study conducted in three tertiary care hospitals, Medical Teaching Institute, Ayub Teaching Hospital (ATH), Abbottabad, North West General Hospital and Research Center, Peshawar and Medical Teaching Institute, Hayatabad Medical Complex (HMC), Peshawar, Pakistan.

Data source {#Sec5}
-----------

The study included data of all consecutive patients, aged \>18 years, who received treatment for cancer during a one-year period, Jan-2014 to Dec-2014. Approval was obtained from hospitals' administrations to access patients' data in order to collect all relevant information needed for the study. Data were collected regarding patients' age, gender, cancer type, comorbidities and prescribed medications.

Data analysis {#Sec6}
-------------

For each patient, medication lists were analyzed for the presence of QT-DDIs using an online database, Micromedex Drug-Reax® \[[@CR19]\]. QT-DDIs were classified on the basis of severity and documentation according to the Micromedex Drug-Reax® classification system \[[@CR19]\]. The Arizona Center for Education and Research on Therapeutics (AZCERT) QT drug list \[[@CR20]\] was used for identifying QT prolonging drugs. The AZCERT classification system categorizes QT prolonging drugs in to list-1 (known risk of TdP), list-2 (possible risk of TdP), and list-3 (conditional risk of TdP). Therapeutic classes of drugs involved in QT-DDIs were coded according to Anatomical Therapeutic Chemical (ATC) index of the World Health Organization (WHO) \[[@CR21]\].

Statistical analyses {#Sec7}
--------------------

Categorical data were presented as frequencies and percentages. While continuous data were presented as mean ± SD. Logistic regression analysis was used to calculate the odds ratios (OR) for predictors of QT-DDIs. A *p*-value ≤0.05 was considered statistically significant. SPSS (IBM SPSS statistics version 23) was used for all statistical analyses.

Results {#Sec8}
=======

Patients' demographic and clinical characteristics are listed in Table [1](#Tab1){ref-type="table"}. Total 555 patients were included in this study, of which 274 (49%) were males and 281 (51%) were females. Mean age of the patients was 46.9 ± 15.7 years, whereas majority of the patients were in the age range \> 50 years (39.5%). Average number of prescribed medications were 8.4 ± 3.6, while in 35.9% of the cases, ≥10 drugs were prescribed. The most frequent diagnoses were breast cancer (15.3%), non-hodgkin lymphoma (15.1%), gastrointestinal cancer (12.8%), gynecologic cancer (5.9%), acute lymphoblastic leukemia (5.2%), and genitourinary cancer (4.1%). The most frequent comorbid illnesses were diabetes mellitus (4.9%), hypertension (4.1%), hepatitis B (0.5%) and hepatitis C (0.5%).Table 1Patients' demographic and clinical characteristicsVariablePatients: n (%)^a^Gender Male274 (49) Female281 (51)Age  ≤ 30120 (21.6) 31--4094 (16.9) 41--50122 (22)  \> 50219 (39.5)Overall prescribed drugs^b^  ≤ 5111 (20) 6--7114 (20.5) 8--9131 (23.6)  ≥ 10199 (35.9)Diagnoses Breast cancer86 (15.5) Non hodgkin lymphoma84 (15.1) Gastrointestinal cancer71 (12.8) Gynecologic cancer33 (5.9) Acute lymphoblastic leukemia29 (5.2) Genitourinary cancer23 (4.1) Hodgkin lymphoma17 (3.1) Chronic lymphocytic leukemia15 (2.7) Musculoskeletal cancer14 (2.5) Acute mylogenous leukemia11 (2) Ovarian cancer11 (2) Colorectal carcinoma11 (2) Lung cancer10 (1.8) Head and neck cancer8 (1.4)Comorbidities Diabetes mellitus27 (4.9) Hypertension23 (4.1) Hepatitis B3 (0.5) Hepatitis C3 (0.5)^a^Percentage calculated in total number of patients i.e., 555^b^Overall prescribed medications mean QT prolonging medications as well as other medications

Total 993 QT prolonging drugs were identified in 92.6% of the patients (Table [2](#Tab2){ref-type="table"}). Among them 46.5% were females while 46.1% were males. The cancer patients were frequently encountered with antiemetics (*n* = 571), proton pump inhibitors (145), antimicrobials (126), anticancer drugs (51) and antineoplastic agents (30) which carried the potential for QT prolongation (Table [2](#Tab2){ref-type="table"}). Total 28 distinct QT prolonging drugs were used in cancer patients. Among them, the most prevalent were ondansetron (*n* = 278), metoclopramide (152), tropisetron (139), ciprofloxacin (90), omeprazole (87), capecitabine (46) and oxaliplatin (30).Table 2Prevalence of the QT interval prolonging drugs with their therapeutic classes and TdP risksPrevalence/ classification schemeFrequencyPatients: *n* (%)^a^Overall prevalence of the QT prolonging drugs514 (92.6)Gender-wise prevalence of QT prolonging drugs Male256 (46.1) Female258 (46.5)Therapeutic classTdP risk^b^QT drug (ATC code)Patients: *n* (%)^a^Antimicrobials (*n* = 126)Known risk of TdP (*n* = 98)Ciprofloxacin (J01MA02)90 (16.2)Clarithromycin (J01FA09)6 (1)Levofloxacin (J01MA12)1 (0.2)Moxifloxacin (J01MA14)1 (0.2)Possible risk of TdP (*n* = 1)Norfloxacin (J01MA06)1 (0.2)Conditional risk of TdP (*n* = 27)Metronidazole (P01AB01)27 (4.9)Anticancer (*n* = 51)Possible risk of TdP (*n* = 51)Capecitabine (L01 BC06)46 (8.3)Tamoxifen (L02BA01)5 (0.9)Antidepressant (*n* = 4)Conditional risk of TdP (*n* = 4)Amitriptyline (N06AA09)3 (0.5)Fluoxetine (N06AB03)1 (0.2)Antidiarrheal (*n* = 1)Conditional risk of TdP (*n* = 1)Loperamide (A07DA03)1 (0.2)Antiemetic (*n* = 571)Known risk of TdP (*n* = 278)Ondansetron (A04AA01)278 (50)Possible risk of TdP (*n* = 141)Tropisetron (A04AA03)139 (25)Promethazine (R06AD02)2 (0.4)Conditional risk of TdP (*n* = 152)Metoclopramide (A03FA01)152 (27.4)Antifungal (*n* = 11)Known risk of TdP (*n* = 6)Fluconazole (J02 AC01)6 (1)Conditional risk of TdP (*n* = 5)Amphotericin B (J02AA01)3 (0.5)Ketoconazole (J02AB02)2 (0.4)Antihistamine (*n* = 8)Conditional risk of TdP (*n* = 8)Diphenhydramine (R06AA52)8 (1.1)Antinausea (*n* = 21)Known risk of TdP (*n* = 21)Domperidone (A03FA03)21 (3.8)Antineoplastic (*n* = 30)Known risk of TdP (*n* = 30)Oxaliplatin (L01XA03)30 (5.4)Antipsychotic (*n* = 1)Known risk of TdP (*n* = 1)Haloperidol (N05 AD01)1 (0.2)Diuretic (*n* = 22)Conditional risk of TdP (*n* = 22)Furosemide (C03CA01)19 (3.4)Hydrochlorothiazide (C03AX01)3 (0.5)Gonadotropin receptor agonist/antagonist (*n* = 1)Possible risk of TdP (*n* = 1)Leuprolide (L02AE02)1 (0.2)Kinase inhibitor (*n* = 1)Possible risk of TdP (*n* = 1)Nilotinib (L01XE08)1 (0.2)Proton pump inhibitor (*n* = 145)Conditional risk of TdP (*n* = 145)Esomeprazole (A02BC05)59 (10.6)Omeprazole (A02BC01)86 (15.5)*AZCERT* Arizona Center for Education and Research on Therapeutics, *TdP* torsades de pointes^a^Percentage calculated in total number of patients i.e., 555^b^TdP risk was based on the AZCERT QT drugs lists

Table [3](#Tab3){ref-type="table"} shows the highly prevalent (*n* [\>]{.ul} 5) QT prolonging drugs used in various types of cancer, such as, breast cancer: ondansetron (54), ciprofloxacin (32), tropisetron (20), and metoclopramide (18); gastrointestinal cancer: ondansetron (46), capecitabine (25), metoclopramide (21), and oxaliplatin (20); and non-hodgkin lymphoma: ondansetron (39), tropisetron (33), metoclopramide (25), and esomeprazole (16). A full presentation of all QT prolonging drugs stratified with respect to various types of cancer has been given in Additional file [1](#MOESM1){ref-type="media"}: Table S1.Table 3Highly prevalent QT interval prolonging drugs (≥5)^a^ in various types of cancerQT drugsTdP risk^b^QT drugs: *n* (%)^c^Breast cancer OndansetronKnown risk of TdP54 (5.4) CiprofloxacinKnown risk of TdP32 (3.2) TropisetronPossible risk of TdP20 (2) MetoclopramideConditional risk of TdP18 (1.8) OmeprazoleConditional risk of TdP8 (0.8) EsomeprazoleConditional risk of TdP6 (0.6)Gastrointestinal cancer OndansetronKnown risk of TdP46 (4.6) CapecitabinePossible risk of TdP25 (2.5) MetoclopramideConditional risk of TdP21 (2.1) OxaliplatinKnown risk of TdP20 (2) TropisetronPossible risk of TdP17 (1.7) OmeprazoleConditional risk of TdP17 (1.7) CiprofloxacinKnown risk of TdP13 (1.3) EsomeprazoleConditional risk of TdP7 (0.7)Non hodgkin lymphoma OndansetronKnown risk of TdP39 (3.9) TropisetronPossible risk of TdP33 (3.3) MetoclopramideConditional risk of TdP25 (2.5) EsomeprazoleConditional risk of TdP16 (1.6) OmeprazoleConditional risk of TdP14 (1.4) CiprofloxacinKnown risk of TdP5 (0.5)Gynecologic cancer OndansetronKnown risk of TdP25 (2.5) TropisetronPossible risk of TdP9 (0.9) CiprofloxacinKnown risk of TdP8 (0.8) MetoclopramideConditional risk of TdP7 (0.7) OmeprazoleConditional risk of TdP7 (0.7) EsomeprazoleConditional risk of TdP5 (0.5)Genitourinary cancer OndansetronKnown risk of TdP18 (1.8) EsomeprazoleConditional risk of TdP5 (0.5)Acute lymphoblastic leukemia MetoclopramideConditional risk of TdP16 (1.6) OmeprazoleConditional risk of TdP16 (1.6) OndansetronKnown risk of TdP7 (0.7) MetronidazoleConditional risk of TdP6 (0.6)Chronic lymphocytic leukemia TropisetronPossible risk of TdP11 (1.1) MetoclopramideConditional risk of TdP8 (0.8)Hodgkin lymphoma OndansetronKnown risk of TdP9 (0.9) MetoclopramideConditional risk of TdP8 (0.8)Musculoskeletal cancer OndansetronKnown risk of TdP9 (0.9) MetoclopramideConditional risk of TdP7 (0.7) TropisetronPossible risk of TdP6 (0.6)Colorectal carcinoma CapecitabinePossible risk of TdP8 (0.8) OxaliplatinKnown risk of TdP7 (0.7) OndansetronKnown risk of TdP5 (0.5)Acute mylogenous leukemia OmeprazoleConditional risk of TdP7 (0.7) MetoclopramideConditional risk of TdP5 (0.5)Lung cancer OndansetronKnown risk of TdP6 (0.6)Neurological cancer OndansetronKnown risk of TdP6 (0.6)Adenocarcinoma MetoclopramideConditional risk of TdP5 (0.5)*AZCERT* Arizona Center for Education and Research on Therapeutics, *TdP* torsades de pointes^a^Remaining results have been mentioned in Additional file [1](#MOESM1){ref-type="media"}: Table S1^b^TdP risk was based on the AZCERT QT drugs lists^c^Percentage calculated in total number of QT interval prolonging drugs i.e., 993

Of 555 patients, 21.8% were presented with QT-DDIs (Fig. [1](#Fig1){ref-type="fig"}). Prevalence of QT-DDIs was higher in females (11.3%) as compared with males (10.5%) (*p* = 0.7) and in age group \>50 years (8.5%) as compared with other age groups (*p* = 0.4). Similarly, prevalence of QT-DDIs was significantly higher in breast cancer (5.8%) and gastrointestinal cancer (5%) compared with other cancers (*p* \< 0.001) and in solid malignancy (17.8%) compared with hematological malignancy (4%) (p \< 0.001) (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Prevalence of QT drug-drug interactions (QT-DDIs) stratified with respect to gender, age, diagnosis and types of malignancy

Total 288 QT-DDIs were identified, of which, all were of major severity and fair documentation (Table [4](#Tab4){ref-type="table"}). According to AZCERT classification, 59.9% of the interacting drugs were included in list-1 (known risk of TdP), 4.7% in list-2 (possible risk of TdP) and 6.8% in list-3 (conditional risk of TdP) (Table [4](#Tab4){ref-type="table"}). As far as therapeutic classes are concerned, antimicrobials (36.3%), antiemetic (34.7%) and antipsychotics (27.3%) were more common. Table [5](#Tab5){ref-type="table"} shows top 20 QT-DDIs, their AZCERT classification, \[[@CR20]\] therapeutic classes, severity and documentation levels. Of the total QT-DDIs, 76 QT-DDIs involved both the interacting drugs from the AZCERT QT drugs list-1 (known risk of TdP). The most common drug interacting pairs involved in QT-DDIs were ondansetron-prochlorperazine (*n* = 88), ciprofloxacin-ondansetron (71), ciprofloxacin-prochlorperazine (64), ciprofloxacin-metronidazole (10) and ciprofloxacin-dolasetron (6). Drugs frequently involved in QT-DDIs were ondansetron (*n* = 174), ciprofloxacin (157), prochlorperazine (157), metronidazole (30), dolasetron (21) and fluconazole (8).Table 4Prevalence of the QT-DDIs, TdP risk, therapeutic classes, severity and documentation of drugs involved in QT DDIsClassification schemeInteracting drugs: *n* (%)^a^TdP risk^b^ Known risk of TdP (List 1)345 (59.9) Possible risk of TdP (List 2)27 (4.7) Conditional risk of TdP (List 3)39 (6.8) Not included in AZCERT QT drug list (List 4)165 (28.6)Therapeutic classes (ATC code) Antimicrobial (J)209 (36.3) Antiemetic (A04)200 (34.7) Antipsychotic (N05A)157 (27.3) Muscle relaxant (M03)3 (0.5) Kinase inhibitor (L01XE)3 (0.5) Antidiarrheal (A)2 (0.4) Anticancer (L01)2 (0.4) Antidepressant (N06A)2 (0.4)Classification on the basis of severity^c^QT-DDIs: *n* (%)^d^Major288 (100)Classification on the basis of documentation^c^QT-DDIs: *n* (%)^d^Fair288 (100)*AZCERT* Arizona Center for Education and Research on Therapeutics, *TdP* torsades de pointes, *QT DDIs* QT prolonging drug-drug interactions, *ATC* Anatomical Therapeutic Chemical^a^Percentage calculated in number of all interacting drugs i.e., 576^b^TdP risk was based on the AZCERT QT drugs lists^c^Severity and documentation were based on Micromedex DrugReax classification^d^Percentage calculated in total number of QT-DDIs i.e., 288 Table 5Top 20 QT drug-drug interaction (QT-DDI) along with their levels, therapeutic class and TdP risks of drugs involved in QT-DDIsQT-DDIsTherapeutic classTdP risk^a^Levels of QT-DDIs^b^FrequencyDrug 1Drug 2Drug 1Drug 2SeverityDocumentationQT-DDIs: *n* (%)^c^Ondansetron-ProchlorperazineAntiemeticAntipsychoticKnown risk of TdPNot included in lists^d^MajorFair88 (30.6)Ciprofloxacin-OndansetronAntimicrobialAntiemeticKnown risk of TdPKnown risk of TdPMajorFair71 (24.7)Ciprofloxacin-ProchlorperazineAntimicrobialAntipsychoticKnown risk of TdPNot included in listsMajorFair64 (22.2)Ciprofloxacin-MetronidazoleAntimicrobialAntimicrobialKnown risk of TdPConditional risk of TdPMajorFair10 (3.5)Ciprofloxacin-DolasetronAntimicrobialAntiemeticKnown risk of TdPPossible risk of TdPMajorFair6 (2.1)Dolasetron -OndansetronAntiemeticAntiemeticPossible risk of TdPKnown risk of TdPMajorFair5 (1.7)Dolasetron-MetronidazoleAntiemeticAntimicrobialPossible risk of TdPConditional risk of TdPMajorFair5 (1.7)Metronidazole-OndansetronAntimicrobialAntiemeticConditional risk of TdPKnown risk of TdPMajorFair4 (1.4)Fluconazole-MetronidazoleAntimicrobialAntimicrobialKnown risk of TdPConditional risk of TdPMajorFair3 (1)Prochlorperazine-PromethazineAntipsychoticAntiemeticNot included in listsPossible risk of TdPMajorFair2 (0.7)Ondansetron-PromethazineAntiemeticAntiemeticKnown risk of TdPConditional risk of TdPMajorFair2 (0.7)Metronidazole-NilotinibAntimicrobialKinase inhibitorConditional risk of TdPConditional risk of TdPMajorFair2 (0.7)Dolasetron-OctreotideAntiemeticAntidiarrhealPossible risk of TdPNot included in listsMajorFair2 (0.7)Clarithromycin-OndansetronAntimicrobialAntiemeticKnown risk of TdPKnown risk of TdPMajorFair2 (0.7)Ciprofloxacin-KetoconazoleAntimicrobialAntimicrobialKnown risk of TdPConditional risk of TdPMajorFair2 (0.7)Ciprofloxacin-FluconazoleAntimicrobialAntimicrobialKnown risk of TdPKnown risk of TdPMajorFair2 (0.7)Prochlorperazine-TrimethoprimAntipsychoticAntimicrobialNot included in listsNot included in listsMajorFair1 (0.3)Prochlorperazine-SulfamethoxazoleAntipsychoticAntimicrobialNot included in listsNot included in listsMajorFair1 (0.3)Ondansetron-TizanidineAntiemeticMuscle relaxantKnown risk of TdPNot included in listsMajorFair1 (0.3)Nilotinib-TizanidineKinase inhibitorMuscle relaxantConditional risk of TdPNot included in listsMajorFair1 (0.3)Metronidazole-TizanidineAntimicrobialMuscle relaxantConditional risk of TdPNot included in listsMajorFair1 (0.3)Metronidazole-ProchlorperazineAntimicrobialAntipsychoticConditional risk of TdPNot included in listsMajorFair1 (0.3)Metronidazole-NorfloxacinAntimicrobialAntimicrobialConditional risk of TdPPossible risk of TdPMajorFair1 (0.3)*AZCERT* Arizona Center for Education and Research on Therapeutics, *TdP* torsades de pointes, *QT DDIs* QT prolonging drug-drug interactions^a^TdP risk was based on AZCERT QT drugs list^b^Levels i.e., severity and documentation were based on Micromedex DrugReax® classification^c^Percentage calculated in total number of QT-DDIs i.e., 288^d^Drugs involved in QT-DDIs were not included in the AZCERT QT drugs lists

Table [6](#Tab6){ref-type="table"} shows the highly prevalent (*n* [\>]{.ul} 2) QT-DDIs in various types of cancer, such as, breast cancer: ciprofloxacin-Ondansetron (31), ciprofloxacin-prochlorperazine (31), and ondansetron-prochlorperazine (31); gastrointestinal cancer: ondansetron-prochlorperazine (26), ciprofloxacin-ondansetron (13), and ciprofloxacin-prochlorperazine (12); and gynecologic cancer: ciprofloxacin-ondansetron (8), ciprofloxacin-prochlorperazine (6), and Ondansetron-Prochlorperazine (6). The entire result has been provided in Additional file [2](#MOESM2){ref-type="media"}: Table S2 which shows frequency of all QT-DDIs along with their levels and TdP risks of drugs involved in these QT-DDIs stratified with respect to various types of cancer.Table 6The most frequent (≥2)^a^ QT-DDIs along with their levels and TdP risks of drugs involved in these QT-DDIs stratified with respect to various types of cancerQT-DDIsTdP riskLevels of QT-DDIsFrequencyDrug 1Drug 2SeverityDocumentationQT-DDIs: *n* (%)^b^Breast cancer Ciprofloxacin-OndansetronKnown risk of TdPKnown risk of TdPMajorFair31 (10.8) Ciprofloxacin-ProchlorperazineKnown risk of TdPNot included in listsMajorFair31 (10.8) Ondansetron-ProchlorperazineKnown risk of TdPNot included in listsMajorFair31 (10.8)Gastrointestinal cancer Ondansetron-ProchlorperazineKnown risk of TdPNot included in listsMajorFair26 (9) Ciprofloxacin-OndansetronKnown risk of TdPKnown risk of TdPMajorFair13 (4.5) Ciprofloxacin-ProchlorperazineKnown risk of TdPNot included in listsMajorFair12 (4.2) Dolasetron-OndansetronPossible risk of TdPKnown risk of TdPMajorFair2 (0.7)Gynecologic cancer Ciprofloxacin-OndansetronKnown risk of TdPKnown risk of TdPMajorFair8 (2.8) Ciprofloxacin-ProchlorperazineKnown risk of TdPNot included in listsMajorFair6 (2.1) Ondansetron-ProchlorperazineKnown risk of TdPNot included in listsMajorFair6 (2.1)Genitourinary cancer Ondansetron-ProchlorperazineKnown risk of TdPNot included in listsMajorFair7 (2.4)Musculoskeletal cancer Ciprofloxacin-OndansetronKnown risk of TdPKnown risk of TdPMajorFair4 (1.4) Ciprofloxacin-ProchlorperazineKnown risk of TdPNot included in listsMajorFair4 (1.4) Ondansetron-ProchlorperazineKnown risk of TdPNot included in listsMajorFair4 (1.4)Chronic lymphocytic leukemia Dolasetron-MetronidazolePossible risk of TdPConditional risk of TdPMajorFair3 (1) Ciprofloxacin-DolasetronKnown risk of TdPPossible risk of TdPMajorFair2 (0.7) Metronidazole-NilotinibConditional risk of TdPConditional risk of TdPMajorFair2 (0.7)Non hodgkin lymphoma Ciprofloxacin-MetronidazoleKnown risk of TdPConditional risk of TdPMajorFair2 (0.7) Ciprofloxacin-OndansetronKnown risk of TdPKnown risk of TdPMajorFair2 (0.7) Ondansetron-ProchlorperazineKnown risk of TdPNot included in listsMajorFair2 (0.7)Adenocarcinoma Ciprofloxacin-OndansetronKnown risk of TdPKnown risk of TdPMajorFair2 (0.7) Ciprofloxacin-ProchlorperazineKnown risk of TdPNot included in listsMajorFair2 (0.7) Ondansetron-ProchlorperazineKnown risk of TdPNot included in listsMajorFair2 (0.7)Head and neck cancer Ciprofloxacin-OndansetronKnown risk of TdPKnown risk of TdPMajorFair2 (0.7) Ciprofloxacin-ProchlorperazineKnown risk of TdPNot included in listsMajorFair2 (0.7) Ondansetron-ProchlorperazineKnown risk of TdPNot included in listsMajorFair2 (0.7)Neurological cancer Ondansetron-ProchlorperazineKnown risk of TdPNot included in listsMajorFair2 (0.7)Chronic myelogenous leukemia Metronidazole-NilotinibConditional risk of TdPConditional risk of TdPMajorFair2 (0.7)*AZCERT* Arizona Center for Education and Research on Therapeutics, *TdP* torsades de pointes, *QT DDIs* QT prolonging drug-drug interactions^a^All results have been mentioned in Additional file [2](#MOESM2){ref-type="media"}: Table S2^b^Percentage calculated in total number of QT-DDIs i.e., 288

In univariate logistic regression analysis (Table [7](#Tab7){ref-type="table"}), a significant association of QT-DDIs with 8--9 prescribed medications (OR = 8.9; 95% CI = 2.6--30.3; *p* \< 0.001), ≥10 prescribed medications (OR = 25.2; 95% CI = 7.7--82.2; *p* \< 0.001), 2 QT prolonging drugs (OR = 25.4; 95% CI = 11.2--57.5; *p* \< 0.001) and ≥3 QT prolonging drugs (OR = 21; 95% CI = 9.2--48; *p* \< 0.001). There was significant association of the occurrence of QT-DDIs with breast cancer (OR = 3.7; 95% CI = 1.2--11.6; *p* = 0.03), gastrointestinal cancer (OR = 4; 95% CI = 1.3--13; *p* = 0.02), 4--5 supportive care drugs (OR = 4.3; 95% CI = 1.9--9.5; *p* \< 0.001), 6--8 supportive care drugs (OR = 8.1; 95% CI = 3.7--17.7; p \< 0.001) and \>8 supportive care drugs (OR = 12.2; 95% CI = 4.9--30.5; *p* \< 0.001).Table 7Logistic regression analysisVariablesOR (95% CI)*p*-valueGender Female1 (0.7--1.6)0.7Age categories  ≤ 30Reference 31--400.8 (0.4--1.7)0.6 41--501.4 (0.8--2.6)0.3  \> 501 (0.6--1.7)1Overall prescribed drugs  ≤ 5Reference 6--73.5 (0.9--12.9)0.07 8--98.9 (2.6--30.3)\<0.001  ≥ 1025.2 (7.7--82.2)\<0.001QT drugs 1Reference 225.4 (11.2--57.5)\<0.001  ≥ 321 (9.2--48)\<0.001Diagnoses Acute lymphoblastic leukemiaReference Breast cancer3.7 (1.2--11.6)0.03 Chronic lymphocytic leukemia3.5 (0.8--15.9)0.1 Gastrointestinal cancer4 (1.3--13)0.02 Genitourinary cancer2.7 (0.7--10.9)0.2 Gynecologic cancer3.1 (0.9--11.2)0.08 Musculoskeletal cancer2.5 (0.5--12)0.3 Non hodgkin lymphoma0.3 (0.07--1.3)0.1 Others1 (0.3--3.3)0.9Anticancer drugs  ≤ 2Reference  \> 20.6 (0.4--0.9)0.02Supportive care drugs  ≤ 3Reference 4--54.3 (1.9--9.5)\<0.001 6--88.1 (3.7--17.7)\<0.001  \> 812.2 (4.9--30.5)\<0.001

Discussion {#Sec9}
==========

This is the first study in oncology which specifically and extensively determined various drug related factors having potential of QT interval prolongation. In this study, we detected a high prevalence of QT prolonging drugs and QT-DDIs, which is of particular concern. Several important findings have emerged from our analysis. The patients with breast cancer and gastrointestinal cancer are at increased risk of TdP due to frequent use of high risk QT interval prolonging medications and QT-DDIs involving both drugs from AZCERT list-1 (known risk of TdP). Proper considerations should be given to monitor the effects of these medications and QT-DDIs in high risk patients. Polypharmacy was the major issue in cancer patients, which might be responsible for such a high prevalence of QT prolonging drugs and QT-DDIs.

The most frequent QT prolonging drugs used in cancer patients were ondansetron, metoclopramide, tropisetron, ciprofloxacin, capecitabine and oxaliplatin which are also responsible for high prevalence of QT-DDIs. While the most common drugs involved in QT-DDIs were ondansetron, metoclopramide, quinolones, capecitabine, oxaliplatin and domperidone. Domperidone is associated with QTc prolongation, subsequent TdP and sudden cardiac death \[[@CR22]\]. The published data suggest that ondansetron, metoclopramide and fluoroquinolones may significantly prolong the QT interval causing serious arrhythmias and mortality \[[@CR23]--[@CR25]\]. The monitoring of arrhythmogenic risks associated with these medications is mandatory to avoid life threatening situations.

The data regarding the prevalence of QT interval prolonging drugs and QT-DDIs in oncology settings are scarce. Over the past few years, a limited number of studies investigated the prevalence of QT-DDIs among cancer patients \[[@CR16]--[@CR18]\]. We identified 288 QT-DDIs in contrast to 45--110 QT-DDIs reported by those studies \[[@CR16]--[@CR18]\]. The lack of consistency in results might be due to a variety of reasons. The study design and various tools used for screening QT-DDIs were different. Moreover, the scope and nature of these studies regarding the prevalence of QT-DDIs was limited.

Previous studies \[[@CR16], [@CR18]\] screened QT-DDIs using AZCERT drug list, \[[@CR20]\] which demonstrates that they considered only pharmacodynamic interactions whereas both pharmacokinetic and pharmacodynamic drug interactions were taken in to account in our analysis. The latest and updated tool, Micromedex Drug-Reax® \[[@CR19]\] was used for screening QT-DDIs along with AZCERT QT drug lists \[[@CR20]\]. A cross-sectional study considered oral anticancer drugs only while we included all drugs in our study \[[@CR16]\]. Variations in prescribing patterns and clinical profile of the patients might me some other factors responsible for these inconsistencies in results. It is quite obvious from our findings that QT-DDIs and their monitoring protocols should be given appropriate consideration in clinical practice.

The prevalence of QT prolonging drugs and QT-DDIs in various types of cancer has not been the subject of studies conducted in past. These parameters were considered in the current study. We identified a high prevalence of QT prolonging drugs and QT-DDIs in breast cancer, gastrointestinal cancer, gynecologic cancer and non-hodgkin lymphoma. The high prevalence of QT-DDIs among cancer patients was due to the frequent use of the QT prolonging drugs. Appropriate considerations are needed to avoid any detrimental effects associated with QT interval prolonging drugs and QT-DDIs. We identified that the potential risk of QT-DDIs increases with rising number of all prescribed medications, QT interval prolonging drugs and supportive care drugs. The patients with breast cancer and gastrointestinal cancer are significantly exposed to QT-DDIs.

Concomitant use of QT prolonging drugs, possibly leading to fatal outcomes, should be avoided \[[@CR26]\]. Several drugs involved in QT-DDIs represented a variety of therapeutic classes such as anticancer, antimicrobials, antiemetics and antipsychotics. QT-DDIs involving these drug classes potentiate the drug induced QTc prolongation and subsequent TdP. There is scarcity of information to guide physicians about the risks of QT-DDIs and this study would definitely help them about this critical area. It is difficult to guess the magnitude of knowledge of health care professionals about the use of QT drugs and QT-DDIs and whether or not they had made any attempts to avoid such drugs or their combinations.

One of the limitations of this study was the lack of ECG data. Consequently, we could not investigate the prevalence of the QTc interval prolongation among cancer patients. This is quite possible that these factors were not considered in routine clinical practice in oncology. In this study, Micromedex DrugReax® was used as a screening tool while other tools are also available and published literature have reported several inconsistencies among these tools \[[@CR27]\].

Conclusion {#Sec10}
==========

The present study shows a high prevalence of QT-DDIs in cancer patients. Various anticancer and supportive care drugs associated with QTc prolongation and TdP are often prescribed concomitantly in oncology, which may lead to lethal arrhythmias. Future studies should further explore the clinical outcomes of QT-DDIs such as QTc prolongation and TdP.

Recommendations {#Sec11}
---------------

The study findings suggest that the QT interval prolongation and subsequent risk of TdP should be considered as an essential component of the patients' monitoring plan in the clinical practice. Moreover, an ECG should be done before starting a QT prolonging drug, 8--12 h after administration of QT prolonging drug or after increasing its dose, as recommended by American College of Cardiology Foundation (ACCF) and American Heart Association (AHA) \[[@CR28]\]. The physicians should be aware of the arrhythmogenic risks associated with the QT interval prolonging drugs and QT-DDIs in oncology ward. In certain cases, where it is inevitable to avoid a QT prolonging drug or its combination, appropriate precautions such as ECG monitoring, dosage adjustment and rectifying the electrolyte imbalance should be undertaken to prevent the potential harmful consequences. The patients with breast cancer and gastrointestinal cancer are considerably exposed to the harmful effects of the QT-DDIs and need special attention. The QT-DDIs involving both the high-risk medications (known risk of TdP) should be particularly avoided. The updated drug information sources such as the AZCERT QT drugs lists \[[@CR20]\] and the Micromedex DrugReax \[[@CR19]\] can be helpful to clinicians regarding the drug selection in oncology.
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